Astellas Pharma Inc

(PINK:ALPMF)

Latest On Astellas Pharma Inc (ALPMF):

Date/Time Type Description Signal Details
2023-05-25 14:36 ESTNewsAstellas Grinds Out A New Target In Stomach And Esophagus CancerN/A
2023-05-23 20:21 ESTNewsBayer, Amgen looked at Iveric before agreeing to Astellas sale - reportN/A
2023-05-12 17:12 ESTNewsAstellas wins FDA approval of hot flashes drug VeozahN/A
2023-05-01 16:16 ESTNewsPfizer, Astellas' Xtandi combo cuts risk of death by 58% in prostate cancer patientsN/A
2023-05-01 04:13 ESTNewsAstellas Pharma agrees to buy Iveric Bio for $5.9 billionN/A
2023-04-29 14:14 ESTNewsAstellas Pharma Inc. (ALPMF) Q4 2022 Earnings Call TranscriptN/A
2023-04-12 10:29 ESTNewsAstellas, CiRA, advance research on medical use of iPS cellsN/A
2023-03-22 20:14 ESTNewsPfizer and Astellas avoid forced price reduction for cancer therapy XtandiN/A
2023-03-17 17:10 ESTNewsPfizer, Astellas' Xtandi meets main goal in phase 3 trial for prostate cancer subtypeN/A
2023-03-10 16:33 ESTNewsAstellas, Seagen's bladder cancer therapy gets review in ChinaN/A
2023-02-20 16:06 ESTNewsFDA extends review period of Astellas fezolinetant to treat menopause symptomsN/A
2023-02-11 09:49 ESTNewsAstellas: Balanced Investment Debate After Q3 NumbersN/A
2023-02-07 00:40 ESTNewsAstellas Pharma Inc. 2023 Q3 - Results - Earnings Call PresentationN/A
2023-02-06 11:39 ESTNewsAstellas Pharma GAAP EPS of ¥103.61, revenue of ¥1.17BN/A
2023-01-26 14:37 ESTNewsCytomX stock rises as Astellas to pay $5M milestone under research pactN/A
2023-01-24 09:31 ESTNewsNovartis' Sandoz to acquire antifungal drug Mycamine from AstellasN/A
2023-01-20 12:20 ESTNewsFDA lifts clinical hold on Astellas' gene replacement therapy trialN/A
2023-01-20 01:00 ESTNewsLeap rebounds as Astellas posts Phase 3 data for rival cancer candidateN/A
2023-01-09 22:47 ESTNewsSelecta Biosciences stock rises 10% on license deal with Astellas for XorkN/A
2023-01-09 10:09 ESTNewsAstellas, Twist Bioscience team up for discovering antibodies for multiple targetsN/A
2022-12-22 06:35 ESTNewsAstellas Pharma, Eisai, Daiichi Sankyo and Takeda join hands to reduce environmental burden in the field of pharmaceutical packagingN/A
2022-12-20 21:34 ESTNewsMerck, Seagen, Astellas combo bladder cancer treatment sBLAs accepted by FDAN/A
2022-12-16 13:22 ESTNewsAstellas zolbetuximab shows survival benefit, meets main goal in 2nd gastric cancer trialN/A
2022-11-17 13:26 ESTNewsAstellas zolbetuximab shows survival benefit, meets main goal in gastric cancer trialN/A
2022-11-01 02:40 ESTNewsAstellas Pharma Inc. (ALPMF) Q3 2022 Earnings Call TranscriptN/A
2022-10-31 10:19 ESTNewsAstellas Pharma GAAP EPS of ¥65.78, revenue of ¥762.18BN/A
2022-10-25 19:22 ESTNewsTaysha Gene stock soars 36% as Astellas to pick 15% stake for $50MN/A
2022-10-04 08:49 ESTNewsAstellas, Pantherna expand collaboration on mRNA-based regenerative medicine programsN/A
2022-09-30 09:57 ESTNewsAstellas' fezolinetant to treat menopause symptoms gets EMA reviewN/A
2022-09-13 03:03 ESTNewsAstellas/Seagen, Merck Padcev/Keytruda combo shows promise in urothelial cancer in trialN/A
2022-09-05 09:23 ESTNewsAstellas reports 1-year safety data of fezolinetant to treat menopause symptomsN/A
2022-08-19 05:30 ESTNewsAstellas fezolinetant to treat menopause symptoms gets FDA reviewN/A
2022-08-10 08:40 ESTNewsVerizon Business selected to power Astellas infrastructureN/A
2022-08-02 23:50 ESTNewsAstellas Pharma announces new medical chiefN/A
2022-08-01 18:47 ESTNewsEledon gets FDA nod to start trial of organ rejection preventing therapyN/A
2022-08-01 18:47 ESTNewsAstellas Pharma GAAP EPS of ¥25.12, revenue of ¥381.79BN/A
2022-08-01 18:47 ESTNewsAstellas Pharma, Inc. (ALPMF) Management on Q1 2022 Results Earnings Call TranscriptN/A
2022-08-01 04:30 ESTNewsAstellas Pharma Inc. 2022 Q1 - Results - Earnings Call PresentationN/A
2022-07-26 10:05 ESTNewsAstellas/Seagen, Merck drug combo shows promise in bladder cancer subtype in trialN/A
2022-07-22 08:18 ESTNewsAstellas to invest $70M to set up new biotech site in South San FranciscoN/A
2022-07-05 23:13 ESTNewsAstellas, Mogrify team up to discover regenerative medicines for hearing lossN/A
2022-06-30 02:43 ESTNewsAstellas subsidiary Mitobridge in license agreement with Generian for undruggable targetsN/A
2022-06-28 14:13 ESTNewsSutro Biopharma soars ~50% after announcing worldwide strategic collaboration with Astellas PharmaN/A
2022-06-27 19:31 ESTNewsAstellas gene replacement therapy trial put on hold by FDA after nerve issue in patientN/A
2022-06-01 07:37 ESTNewsAstellas unit to pay $20.5M upfront to GO Therapeutics in collaboration to discover cancer therapiesN/A
2022-04-28 06:11 ESTNewsAstellas Pharma, Inc. (ALPMF) CEO Kenji Yasukawa on Q4 2022 Results - Earnings Call TranscriptN/A
2022-04-27 14:50 ESTNewsAstellas Pharma GAAP EPS of ¥103.03, revenue of ¥1296.16B beats by ¥1285.85BN/A
2022-03-07 12:02 ESTNewsAstellas' phase 3 trial of fezolinetant to treat menopause symptoms meets main goalN/A
2022-01-19 21:05 ESTNewsESSA Pharma begins dosing of EPI-7386 in phase 1/2 prostate cancer studyN/A
2021-10-29 09:54 ESTNewsAstellas Pharma reports 1H resultsN/A

About Astellas Pharma Inc (ALPMF):

Astellas Pharma Inc. engages in the manufacture, marketing, import, and export of pharmaceuticals worldwide. It provides XTANDI, an androgen receptor signaling inhibitor for prostate cancer; XOSPATA, a FLT3 inhibitor for adult patients with relapsed or refractory acute myeloid leukemia with a FLT3 mutation-positive; PADCEV, a treatment solution for adult patients with locally advanced or metastatic urothelial cancer; Betanis/Myrbetriq/BETMIGA, a beta-3 adrenergic receptor agonist for the treatment of urgency, urinary frequency, and urge urinary incontinence; Evrenzo, an oral treatment for anemia associated with chronic kidney disease; and Prograf and Advagraf/Graceptor/ASTAGRAF, which are immunosuppressants used to suppress organ rejection following a transplant. The company also offers mirabegron for the treatment of neurogenic detrusor overactivity in pediatric patients; Vesicare for OAB treatment; Eligard to treat prostate cancer; Harnal/Omnic for benign prostatic hyperplasia treatment; and Funguard/MYCAMINE, an antifungal agent. The company has a clinical trial collaboration with Merck & Co., Inc.; CytomX Therapeutics, Inc.; and an agreement with BANDAI NAMCO Entertainment Inc. for the development of smartphone exercise support application. It also has strategic research alliance with Harvard University for the research and development of therapeutics and technologies of mutual interest; and research collaboration with Actinium Pharmaceuticals, Inc. to develop targeted radiotherapies using its Antibody Warhead Enabling technology platforms. Astellas Pharma Inc. was founded in 1923 and is headquartered in Tokyo, Japan.

ALPMF Quotes by TradingView

See Advanced Chart

General

  • Name Astellas Pharma Inc
  • Symbol ALPMF
  • Type Common Stock
  • Exchange PINK
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryDrug Manufacturers-General
  • Full Time Employees 15,883
  • Last Split Factor5:1
  • Last Split Date2014-03-27
  • Fiscal Year EndMarch
  • Web URLhttp://www.astellas.com
View More

Valuation

  • Trailing PE 19.61
  • Forward PE 13.76
  • Price/Sales (Trailing 12 Mt.) 2.71
  • Price/Book (Most Recent Quarter) 2.48
  • Enterprise Value Revenue 0.02
  • Enterprise Value EBITDA 0.12
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Profit Margin 11%
  • Return on Assets 5%
  • Return on Equity 10%
  • Earnings Per Share $0.85
  • Revenue Per Share $0
  • Gross Profit 1.02 trillion
  • Quarterly Earnings Growth -3.7%
View More

ESG Rating

  • Rating Date 2019-01-01
  • ESG Score 18
  • Environment Score 3.72
  • Social Score 10.92
  • Governance Score 6.8
  • Controversy Level 2
View More

Highlights

  • Market Capitalization 30.88 billion
  • Analyst Target Price $50
  • Book Value Per Share $6.06
View More

Share Statistics

  • Shares Outstanding 1.86 billion
  • Shares Float 1.86 billion
  • % Held by Insiders 58%
  • % Held by Institutions 56.82%
View More

Technicals

  • Beta 0.56
  • 52 Week High $17.72
  • 52 Week Low $12.68
  • 50 Day Moving Average 16.48
  • 200 Day Moving Average 15.32
View More

Dividends

  • Forward Annual Dividend Rate $0.39
  • Forward Annual Dividend Yield 2.31%
  • Payout Ratio 59%
  • Dividend Date 2018-06-18
  • ExDividend Date 2020-09-29
  • Dividend Per Share $0.34
  • Dividend Yield 0%
View More

Astellas Pharma Inc (ALPMF) Dividend Calendar:

ALPMF's last dividend payment was made to shareholders on June 18, 2018.
Astellas Pharma Inc pays out 59% of its earnings out as a dividend.

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Astellas Pharma Inc (ALPMF) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312020-12-31$N/A$0.31
2020-09-302020-12-31$N/A$0.31
2020-06-302020-09-30$N/A$0.11
2020-03-312020-06-30$N/A$0.25
2019-12-312020-03-31$3.11 billion$0.03
2019-09-302019-12-31$2.93 billion$0.30
2019-06-302019-09-30$3.09 billion$0.34
2019-03-312019-06-30$2.71 billion$0.29
2018-12-312019-03-31$3.27 billion$0.15
2018-09-302018-12-31$2.79 billion$0.42
2018-06-302018-09-30$2.97 billion$0.22
2018-03-312018-06-30$2.84 billion$0.25$16.58-98.49%
2017-12-312018-03-31$3.19 billion$0.10$29.60-99.65%
2017-09-302017-12-31$2.81 billion$0.27$24.50-98.91%
2017-06-302017-09-30$322.57 billion$0.17$26.22-99.34%
2017-03-312017-06-30$306.08 billion$0.18$11.18-98.37%
2016-12-312017-03-31$0.17$25.99-99.34%
2016-09-302016-12-31$0.26$21.19-98.78%
2016-06-302016-09-30$0.22$24.49-99.08%
2016-03-312016-06-30$0.30$4.70-93.51%
2015-12-312016-03-31$0.12$22.25-99.45%
2015-09-302015-12-31$0.24$18.24-98.69%
2015-06-302015-09-30$0.22$20.84-98.92%
2015-03-312015-06-30$0.17$11.95-98.61%
2014-12-312015-03-31$0.08
2014-09-302014-12-31$0.17
2014-06-302014-09-30$0.14
2014-03-312014-06-30$0.16$0.00
2013-12-312014-03-31$0.04
2013-09-302013-12-31$0.14
2013-06-302013-09-30$0.12
2013-03-312013-06-30$0.10
2012-12-312013-03-31-$0.01
2012-09-302012-12-31$0.14
2012-06-302012-09-30$0.12
2012-03-312012-06-30$0.19
2011-12-312012-03-31-$0.11
2011-09-302011-12-31$0.27
2011-06-302011-09-30$0.15
2011-03-312011-06-30$0.13
2010-12-312011-03-31-$0.06
2010-09-302010-12-31$0.19
2010-06-302010-06-30$0.19
2010-03-312010-03-31$0.03
2009-03-312009-05-13$0.08-$0.27130.59%
2008-12-312008-12-31$0.27
2008-09-302008-09-30$0.18
2008-06-302008-06-30$0.17

Astellas Pharma Inc (ALPMF) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date Dec 31 2020 Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019
Research Development N/A N/A N/A N/A 504.3 million
Income Before Tax N/A N/A N/A N/A 714.4 million
Selling General Administrative N/A N/A N/A N/A 1.17 billion
Gross Profit N/A N/A N/A N/A 2.35 billion
Ebit N/A N/A N/A N/A 701.07 million
Operating Income N/A N/A N/A N/A 701.07 million
Income Tax Expense 15.06 billion 6.43 billion 9.83 billion 775 million 148.29 million
Total Revenue N/A N/A N/A N/A 3.11 billion
Cost of Revenue N/A N/A N/A N/A 761.98 million
Total Other Income Expense Net N/A N/A N/A N/A 13.33 million
Net Income From Continuing Operations N/A N/A N/A N/A 566.11 million
Net Income Applicable to Common Shares 60.08 billion 22.43 billion 50.41 billion 5.39 billion 566.11 million
Cash Flow:
Date Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019 Sep 30 2019
Investments N/A N/A N/A N/A N/A
Change to Liabilities -20.58 billion -30.22 billion 21.32 billion -167.28 million 189.5 million
Total Cash Flow from Investing Activities -9.96 billion -28.33 billion -315.41 billion -256.23 million -301.33 million
Net Borrowings -36.23 billion -34.3 billion 320.98 billion -40.86 million N/A
Total Cash Flow from Financial Activities N/A N/A N/A -729.81 million -51.83 million
Change to Operating Activities 10.56 billion -10.56 billion 1.72 billion -111.61 million -292.14 million
Change in Cash N/A N/A N/A -310.84 million 480.62 million
Total Cash from Operating Activities 93.36 billion 21.6 billion 51.71 billion 631.82 million 872.01 million
Depreciation N/A N/A N/A 157.87 million 130.77 million
Other Cash Flow from Investing Activities -150 million 6.59 billion 13.64 billion -23.34 million -99.85 million
Change to Inventory N/A N/A N/A 33.1 million -10.19 million
Change to Account Receivables N/A N/A N/A -207.04 million 139.4 million
Other Cash Flow from Financing Activities -532 million -645 million 153 million -2.4 million -40.86 million
Change to Net Income 31.67 billion 10.39 billion -2.82 billion 360.67 million -72.31 million
Capital Expenditures N/A N/A N/A 133.67 million 85.31 million
Balance Sheet:
Date Dec 31 2020 Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019
Total Liabailities N/A N/A N/A N/A 6.19 billion
Total Stockholder Equity N/A N/A N/A N/A 12.13 billion
Other Current Liabilities 359.85 billion 503.42 billion N/A N/A 3 billion
Total Assets N/A N/A N/A N/A 18.32 billion
Common Stock 103 billion 103 billion 103 billion 103 billion 948.23 million
Other Current Assets 19.24 billion 22.73 billion N/A N/A 175.25 million
Retained Earnings 963.01 billion 941.85 billion 918.89 billion 905.85 billion 8.74 billion
Other Liabilities 292.39 billion 290.46 billion 301.68 billion 230.28 billion 1.9 billion
Other Assets 95.41 billion 99.45 billion 99.81 billion 97.07 billion 1.17 billion
Cash N/A N/A N/A N/A 2.56 billion
Total Current Liabilities 635.85 billion 616.93 billion N/A N/A 4.29 billion
Other Stockholder Equity 132.14 billion 114.64 billion 115.03 billion 109.99 billion 1.19 billion
Property, Plant & Equipment 255.18 billion 265.67 billion 267.11 billion 268.6 billion 2.4 billion
Total Current Assets 863.29 billion 819.9 billion N/A N/A 7.68 billion
Long Term Investments N/A N/A N/A N/A 783.31 million
Net Tangible Assets 403.65 billion 368.93 billion 300.41 billion 283.15 billion 5.85 billion
Short Term Investments N/A N/A N/A N/A 41.78 million
Long Term Debt N/A N/A N/A N/A N/A
Inventory 155.74 billion 155.74 billion N/A N/A 1.37 billion
Accounts Payable 111 billion 113.51 billion N/A N/A 1.29 billion

Astellas Pharma Inc (ALPMF) Chart:

Astellas Pharma Inc (ALPMF) News:

Below you will find a list of latest news for Astellas Pharma Inc (ALPMF) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Astellas Pharma Inc (ALPMF) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent

Astellas Pharma Inc (ALPMF) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2008-10-21F-6EFRegistration of American Depository Receipt shares, immediately effectivehttps://www.sec.gov/Archives/edgar/data/1446390/000101915508000579/0001019155-08-000579-index.htm
2013-05-13F-6 POSPost-effective amendments for immediately effective filinghttps://www.sec.gov/Archives/edgar/data/1446390/000101915513000253/0001019155-13-000253-index.htm
2014-04-02F-6 POSPost-effective amendments for immediately effective filinghttps://www.sec.gov/Archives/edgar/data/1446390/000101915514000133/0001019155-14-000133-index.htm
2008-10-10F-6EFRegistration of American Depository Receipt shares, immediately effectivehttps://www.sec.gov/Archives/edgar/data/1446390/000110465908063346/0001104659-08-063346-index.htm
2008-10-27F-6EFRegistration of American Depository Receipt shares, immediately effectivehttps://www.sec.gov/Archives/edgar/data/1446390/000119380508002488/0001193805-08-002488-index.htm
2013-02-13F-6EFRegistration of American Depository Receipt shares, immediately effectivehttps://www.sec.gov/Archives/edgar/data/1446390/000119380513000347/0001193805-13-000347-index.htm
2013-05-03F-6 POSPost-effective amendments for immediately effective filinghttps://www.sec.gov/Archives/edgar/data/1446390/000119380513000881/0001193805-13-000881-index.htm
2013-05-06F-6 POSPost-effective amendments for immediately effective filinghttps://www.sec.gov/Archives/edgar/data/1446390/000119380513000898/0001193805-13-000898-index.htm
2013-05-13F-6 POSPost-effective amendments for immediately effective filinghttps://www.sec.gov/Archives/edgar/data/1446390/000119380513000938/0001193805-13-000938-index.htm
2014-03-20F-6 POSPost-effective amendments for immediately effective filinghttps://www.sec.gov/Archives/edgar/data/1446390/000119380514000509/0001193805-14-000509-index.htm
2014-03-24F-6 POSPost-effective amendments for immediately effective filinghttps://www.sec.gov/Archives/edgar/data/1446390/000119380514000557/0001193805-14-000557-index.htm
2014-03-24F-6 POSPost-effective amendments for immediately effective filinghttps://www.sec.gov/Archives/edgar/data/1446390/000119380514000561/0001193805-14-000561-index.htm
2017-09-29F-6 POSPost-effective amendments for immediately effective filinghttps://www.sec.gov/Archives/edgar/data/1446390/000119380517002836/0001193805-17-002836-index.htm
2017-12-21F-6EFRegistration of American Depository Receipt shares, immediately effectivehttps://www.sec.gov/Archives/edgar/data/1446390/000119380517003626/0001193805-17-003626-index.htm
2019-11-22F-6EFRegistration of American Depository Receipt shares, immediately effectivehttps://www.sec.gov/Archives/edgar/data/1446390/000119380519001576/0001193805-19-001576-index.htm
2014-10-15F-6EFRegistration of American Depository Receipt shares, immediately effectivehttps://www.sec.gov/Archives/edgar/data/1446390/000157104914005109/0001571049-14-005109-index.htm